GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CSL Ltd (OTCPK:CSLLY) » Definitions » EV-to-FCF

CSL (CSLLY) EV-to-FCF : 83.69 (As of May. 02, 2024)


View and export this data going back to 2008. Start your Free Trial

What is CSL EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, CSL's Enterprise Value is $96,966 Mil. CSL's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $1,159 Mil. Therefore, CSL's EV-to-FCF for today is 83.69.

The historical rank and industry rank for CSL's EV-to-FCF or its related term are showing as below:

CSLLY' s EV-to-FCF Range Over the Past 10 Years
Min: 31.66   Med: 70.78   Max: 306.09
Current: 86.32

During the past 13 years, the highest EV-to-FCF of CSL was 306.09. The lowest was 31.66. And the median was 70.78.

CSLLY's EV-to-FCF is ranked worse than
86.96% of 391 companies
in the Biotechnology industry
Industry Median: 4.48 vs CSLLY: 86.32

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-02), CSL's stock price is $91.17. CSL's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $2.545. Therefore, CSL's PE Ratio for today is 35.82.


CSL EV-to-FCF Historical Data

The historical data trend for CSL's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CSL EV-to-FCF Chart

CSL Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 199.28 84.53 52.81 65.39 112.78

CSL Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 65.39 - 112.78 -

Competitive Comparison of CSL's EV-to-FCF

For the Biotechnology subindustry, CSL's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CSL's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CSL's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where CSL's EV-to-FCF falls into.



CSL EV-to-FCF Calculation

CSL's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=96966.348/1158.6
=83.69

CSL's current Enterprise Value is $96,966 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CSL's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $1,159 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CSL  (OTCPK:CSLLY) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

CSL's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=91.17/2.545
=35.82

CSL's share price for today is $91.17.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CSL's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $2.545.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


CSL EV-to-FCF Related Terms

Thank you for viewing the detailed overview of CSL's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


CSL (CSLLY) Business Description

Traded in Other Exchanges
Address
655 Elizabeth Street, Melbourne, VIC, AUS, 3000
CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include non-plasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.